发布求助
文献互助 智能选刊 最新文献

Skinmed最新文献

筛选
英文 中文
Effectiveness and Safety of Azathioprine versus PUVA-SOL as Steroid-Sparing Agents in the Treatment of Unstable Vitiligo. 硫唑嘌呤与 PUVA-SOL 作为类固醇稀释剂治疗不稳定型白癜风的有效性和安全性。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Rahul Nagar, Usha Mandloi, Minal Singh, Saurabh Dubey, Sanjay Khare
{"title":"Effectiveness and Safety of Azathioprine versus PUVA-SOL as Steroid-Sparing Agents in the Treatment of Unstable Vitiligo.","authors":"Rahul Nagar, Usha Mandloi, Minal Singh, Saurabh Dubey, Sanjay Khare","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Vitiligo is an acquired chronic loss of skin pigmentation characterized by white and frequent symmetric patches, for which corticosteroids are the mainstay of treatment. Regular intake of steroids for prolonged periods is frequently associated with severe and sometimes irreversible adverse events. This study was designed to compare the effectiveness and safety profiles of azathioprine versus psoralen+ultraviolet light A (PUVA)-solar light (SOL; sunlight) to determine which agent reduces the length and adverse effects of vitiligo therapy in a better manner. This single-center, randomized, open-label, prospective case-control study recruited 100 patients. Oral mini-pulse (OMP) corticosteroid therapy was administered to all patients during the first month of the study. The first group of patients (group A) continued with azathioprine 50-mg tablet twice a day (BID), and the second group (group B) was given PUVA-SOL for 2 months with concurrent OMP. Disease activity was monitored. At the end of the study period, 58% (group A) and 50% (group B) of patients had their improved vitiligo area severity index (VASI) scores by 25%-50%. Similarly, 36% (group A) and 50% (group B) of patients improved their VASI score by more than 50%. On the global physician assessment scale, 42% (group A) and 54% (group B) patients had a good to excellent response. Based on these findings, both azathioprine and PUVA-SOL were considered as good steroid-sparing agents, primarily if used with an initial phase of concomitant oral corticosteroids.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Animal Signs in Dermatology: A Furry Approach to Remembering Various Dermatologic Conditions. 皮肤病学中的动物体征：记住各种皮肤病的毛茸茸方法。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Niki Nourmohammadi, Jere Mammino, William Abramovits
{"title":"Animal Signs in Dermatology: A Furry Approach to Remembering Various Dermatologic Conditions.","authors":"Niki Nourmohammadi, Jere Mammino, William Abramovits","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammatory Linear Verrucous Epidermal Naevus Patient Treated Successfully with Low-Dose Acitretin. 炎性线状疣状表皮痣患者成功接受小剂量阿曲汀治疗
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Geetika Chhabra, Prashant Verma
{"title":"Inflammatory Linear Verrucous Epidermal Naevus Patient Treated Successfully with Low-Dose Acitretin.","authors":"Geetika Chhabra, Prashant Verma","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reddit Analysis Reveals Common Questions of Patients with Alopecia Areata about JAK Inhibitors for Hair Loss. Reddit 分析揭示了脱发患者关于 JAK 抑制剂治疗脱发的常见问题。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Hailey Konisky, Emely Tejeda, Eliza Balazic, Kseniya Kobets
{"title":"Reddit Analysis Reveals Common Questions of Patients with Alopecia Areata about JAK Inhibitors for Hair Loss.","authors":"Hailey Konisky, Emely Tejeda, Eliza Balazic, Kseniya Kobets","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Full Face Application of Topical Platelet Extract for Skin Rejuventation in Monozygotic Twins. 在单卵双生子中全面应用局部血小板提取物进行皮肤再造。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Sydney Proffer, Yael Halaas, K Kay Durairaj, Michael Somenek, Atta Behfar, Saranya P Wyles
{"title":"Full Face Application of Topical Platelet Extract for Skin Rejuventation in Monozygotic Twins.","authors":"Sydney Proffer, Yael Halaas, K Kay Durairaj, Michael Somenek, Atta Behfar, Saranya P Wyles","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Two monozygotic twins (Fitzpatrick skin type II 56-year-old women) with significant photoaging and mild to moderate global fine lines based on the modified Griffiths 10-point scale were enrolled in the study. The past medical etymology and laboratory evaluation were unremarkable. Each subject followed a standardized skin care regimen with topical platelet renewosomes<sup>TM</sup> (human platelet extract [HPE]) daily for a 12-week duration.<sup>1-4</sup> In order to evaluate aesthetic outcomes/changes subjectively, three blinded board-certified plastic surgeons (Yael Halaas, K. Kay Durairaj, and Michael Somenek) compared photographs between baseline and 12-week follow-up (Figure 1). This evaluation was completed using the Global Aesthetic Improvement Scale (GAIS) and the modified Griffiths 10-point scale.<sup>5,6</sup>.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Morphea Associated with Adalimumab Treatment: The Role of TNF-α in Inhibition of Fibrosis. 与阿达木单抗治疗相关的斑秃：TNF-α 在抑制纤维化中的作用
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Tamara Gracia-Cazaña, Victoria Fuentelsaz, Alba Navarro-Bielsa, Emilio Giner-Serret, Francisco Javier García-Latasa
{"title":"Morphea Associated with Adalimumab Treatment: The Role of TNF-α in Inhibition of Fibrosis.","authors":"Tamara Gracia-Cazaña, Victoria Fuentelsaz, Alba Navarro-Bielsa, Emilio Giner-Serret, Francisco Javier García-Latasa","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Anti-tumor necrosis factor alpha (anti-TNF-α) comprises a group of drugs that inhibit the action of cytokine TNF-α, and are used to treat diseases mainly caused by this cytokine. An increase in cutaneous adverse events has been observed with similar anti-TNF biologic treatments frequently used in clinical practice.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lichen Sclerosus in Perspective. 透视硬皮病。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Alison Romisher, Casey L Ross, Nicholas A Ross
{"title":"Lichen Sclerosus in Perspective.","authors":"Alison Romisher, Casey L Ross, Nicholas A Ross","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Lichen sclerosus (LS) was first described in women by a researcher in 1887.<sup>1</sup> It was recognized in men by another investigator in 1928.<sup>2</sup> Lichen sclerosus is a chronic, inflammatory lymphocytic dermatosis that occurs in anywhere from 1:30 to 1:1,000 adults.<sup>3,4</sup> There is a slight predominance of women, with a bimodal age distribution in pre-pubertal individuals and again in life's sixth-seventh decades. Studies have established that the majority with pre-pubertal onset continue to have adulthood disease.<sup>5</sup> Psychosocial implications of this disease, specifically self-image, anxiety, and sexual function, can be debilitating for patients.<sup>6-9</sup> As no cure has been described for lichen sclerosus. Treatment is aimed at symptomatic relief and preventing additional effacement. Unfortunately, the scarring that occurs is usually permanent.<sup>10,11</sup> As it is unclear whether treatment alters the theoretic risk of malignant degeneration, estimated at 4%-5%,<sup>12,13</sup> frequent clinical examinations are indicated.<sup>14-17</sup>.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DAXXIFYTM (DaxibotulinumtoxinA-Lanm) for Injection, for Intramuscular Use. 注射用 DAXXIFYTM（DaxibotulinumtoxinA-Lanm），用于肌肉注射。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Aditya K Gupta, Avantika Mann, Kimberly Vincent, William Abramovits
{"title":"DAXXIFY<sup>TM</sup> (DaxibotulinumtoxinA-Lanm) for Injection, for Intramuscular Use.","authors":"Aditya K Gupta, Avantika Mann, Kimberly Vincent, William Abramovits","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>DAXXIFY<sup>TM</sup> (daxibotulinumtoxinA-lanm) for intramuscular injection was recently approved for temporary improvement in the appearance of the moderate to severe glabellar lines (GLs) associated with corrugator and/or procerus muscle activity in adult patients. DaxibotulinumtoxinA for Injection (DAXI) includes a purified 150-kDA botulinum toxin Type A (BoNTA) formulated with a novel peptide excipient that is positively charged and helps to bind the neurotoxin to negatively charged neuronal membrane for a longer duration. The effectiveness of DAXI was evaluated in two phase 3 trials, SAKURA 1 and SAKURA 2, using a randomized, double-blind, placebo-controlled design. The primary endpoint (treatment success) was a composite clinical outcome (investigator and subjects) of ≥2-point improvement in severity of GLs at week 4. In SAKURA 1, the treatment success was 74% (148/201) in subjects treated with DAXI and 0% in subjects treated with placebo. In SAKURA 2, the treatment success was 74% (152/205) in subjects treated with DAXI and 0% in subjects treated with placebo. An open-label study, SAKURA 3, included 2,691 participants, who underwent three consecutive treatment cycles. These individuals were recruited from either SAKURA 1 or SAKURA 2 trials, or were new to the study and received DAXI. Treatment success proportions were 73.2%, 77.7%, and 79.6% across the three consecutive treatment cycles. The recommended dose is 40 units for the Glabellar-complex divided in traditional five intramuscular injections at five injection sites (medial and lateral corrugator bilaterally and one injection in the procerus muscle).</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Juvenile Dermatomyositis: Diagnosis and Management. 幼年皮肌炎：诊断与管理。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Amina Aounallah, Sarra Saad, Nadia Ghariani Fetouri, Mohamed Denguezli
{"title":"Juvenile Dermatomyositis: Diagnosis and Management.","authors":"Amina Aounallah, Sarra Saad, Nadia Ghariani Fetouri, Mohamed Denguezli","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Juvenile dermatomyositis (JDM) is the leading cause of chronic idiopathic inflammatory myopathy of auto-immune origin in children.<sup>1</sup> Seven patients with JDM found in the records from 1998-2019 of the Department of Dermatology Farhat Hached Hospital, Sousse, Tunisia. Our study concerned a total of six girls and one boy with a median age at disease onset of 8,16 years.<sup>2</sup> The average time before diagnosis was 8,8 months. The onset of the disease was acute in 2 patients. All patients displayed skin manifestations at diagnosis, with proximal muscular weakness in 4 cases. Four patients had elevated muscle enzymes and all of them showed myopathic findings on electromyography. Oral corticosteroids were prescribed in 6 patients, in association with other systemic therapies. Three patients achieved a good outcome while two others relapsed. The two other patients showed corticosteroids resistance with a fatal outcome in one case. This study highlights the diagnostic features and management of juvenile dermatomyositis.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Childhood Acral Acanthosis Associated with Obesity. 与肥胖有关的儿童痤疮。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Avita Dhiman, Manmohan Bagri, Neirita Hazarika
{"title":"Childhood Acral Acanthosis Associated with Obesity.","authors":"Avita Dhiman, Manmohan Bagri, Neirita Hazarika","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信